Consistent with studies reported previously in other cancers [43,44,45,46,47,48], the results of the present study further confirmed that the circulating concentrations of AnxA2 in serum could be used as a diagnostic and prognostic serological biomarker for breast cancer patients. Here, ANXA2 is linked to breast carcinoma.